UA50462A - Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением - Google Patents
Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением Download PDFInfo
- Publication number
- UA50462A UA50462A UA2002010446A UA200210446A UA50462A UA 50462 A UA50462 A UA 50462A UA 2002010446 A UA2002010446 A UA 2002010446A UA 200210446 A UA200210446 A UA 200210446A UA 50462 A UA50462 A UA 50462A
- Authority
- UA
- Ukraine
- Prior art keywords
- day
- days
- women
- drug
- dose
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 28
- 235000020824 obesity Nutrition 0.000 title claims abstract description 28
- 230000035935 pregnancy Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 230000003054 hormonal effect Effects 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 18
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 18
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 9
- 235000012054 meals Nutrition 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 30
- 230000035606 childbirth Effects 0.000 claims description 14
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 4
- 238000010606 normalization Methods 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 3
- 238000012876 topography Methods 0.000 claims 1
- 230000000141 anti-hypoxic effect Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 208000037805 labour Diseases 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 14
- 230000037396 body weight Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 230000007170 pathology Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000009984 peri-natal effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 108010003044 Placental Lactogen Proteins 0.000 description 2
- 239000000381 Placental Lactogen Substances 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 description 1
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KURZCZMGELAPSV-UHFFFAOYSA-N [Br].[I] Chemical compound [Br].[I] KURZCZMGELAPSV-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229950001485 cocarboxylase Drugs 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 201000011460 mild pre-eclampsia Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением включает в себя дородовую терапию, направленную на нормализацию гормонального и липидного обмена. Для нормализации гормонального и липидного обмена, начиная с третьего триместра беременности, в1-й, 3-й и 5-й дни лечения вводят антиоксидантный препарат Хофитол в дозе 5-10 мл внутривенно капельно один раз в день. Во 2-й, 4-й и 6-й день вводят антиоксидантный и антигипоксантный препарат Липин в дозе 500-750 мг стерильного лиофилизированного препарата внутривенно капельно медленно один раз в день с переходом с 7-го дня лечения на таблетированную форму Хофитола в дозе по 2 таблетки 3 раза в день за 15 минут перед приемом пищи при общей продолжительности курса лечения 20 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002010446A UA50462A (ru) | 2002-01-17 | 2002-01-17 | Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002010446A UA50462A (ru) | 2002-01-17 | 2002-01-17 | Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA50462A true UA50462A (ru) | 2002-10-15 |
Family
ID=74235738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002010446A UA50462A (ru) | 2002-01-17 | 2002-01-17 | Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA50462A (ru) |
-
2002
- 2002-01-17 UA UA2002010446A patent/UA50462A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050196434A1 (en) | Pharmaceutical composition and method for the transdermal delivery of magnesium | |
| RU2466734C1 (ru) | Капли плетнева для восстановления метаболизма и энергообеспечения тканей и органов | |
| Furkatovna | EFFECT OF VITAMIN D DICTION ON BONE MINERAL DENSITY IN MENOPAUSA WOMEN | |
| US11596166B2 (en) | Compositions and methods for treating aging and/or improving human health | |
| Furkatovna | Vitamin D Deficiency in Menopausa Women | |
| RU2498811C1 (ru) | Способ профилактики и лечения остеопороза и переломов костей и препарат для профилактики и лечения остеопороза и переломов костей | |
| JP7257399B2 (ja) | 多嚢胞性卵巣症候群に罹患している女性患者における胚着床率を高める方法 | |
| JPS60100520A (ja) | 周閉経期、閉経期および閉経期後の障害をホルモン的に治療する医薬品組成物 | |
| WILLERT et al. | Association of prune belly syndrome and gastroschisis | |
| UA50462A (ru) | Способ профилактики осложнений беременности и родов у женщин с алиментарно-конституционным ожирением | |
| Brown | Relactation with reference to application in developing countries | |
| WO2003022292A1 (fr) | Formulation pharmaceutique orale contenant du charbon actif et utilisation de cette formulation | |
| RU2327462C1 (ru) | Способ лечения маточных кровотечений пубертатного периода | |
| APPEL et al. | Insulin in Undernutrition in the Psychoses | |
| Persley et al. | Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis | |
| EP4193992A1 (en) | New composition and uses thereof | |
| Ansari et al. | Thyrotoxicosis in a mongol. | |
| US20180193312A1 (en) | Nutraceutical composition and dosing regimen | |
| RU2424817C1 (ru) | Способ профилактики и лечения угрозы прерывания беременности у женщин с миомой матки согласно новому взгляду на ее этиопатогенез | |
| Dunea | Letter from... Chicago. Shopping-bag syndrome. | |
| Ngo-Hamilton | Estradiol Vaginal Cream for Menopause: How it Works-BuzzRx | |
| RU2573992C1 (ru) | Способ продления молодости и достижения активного долголетия | |
| RU2086242C1 (ru) | Способ лечения невынашивания беременности | |
| JPS6261925A (ja) | 脂質代謝促進剤 | |
| RU2277917C2 (ru) | Способ антенатальной профилактики нарушений здоровья новорожденных |